AstraZeneca vs Pfizer vs Amgen and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: AstraZeneca 15.384, Pfizer 15.034, Amgen 10.054, Roche 17.5245.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, AstraZeneca, Pfizer, Amgen, Roche.| Metric | AstraZeneca | Pfizer | Amgen | Roche |
|---|---|---|---|---|
| Market Cap | $257.42B | $159.99B | $237.52B | $370.34B |
| Revenue | $15.38B | $15.03B | $10.05B | $35.05B |
| Cost of Revenue | $2.52B | $4.09B | $2.81B | $9.21B |
| Gross Profit | $12.86B | $10.94B | $7.24B | $25.84B |
| Operating Income | $3.16B | $4.71B | $3.51B | $10.90B |
| Net Income | $2.51B | $-246.00M | $2.38B | $7.93B |
| R&D Expense | $4.05B | $2.81B | $1.87B | $8.35B |
| Earnings Per Share | $1.59 | -$0.04 | $4.37 | $1.23 |
| Gross Margin | 83.6% | 72.8% | 72.0% | 73.7% |
| Operating Margin | 20.6% | 31.3% | 35.0% | 31.1% |
| Net Profit Margin | 16.3% | -1.6% | 23.6% | 22.6% |
| Free Cash Flow | $2.13B | $302.00M | $3.49B | $6.46B |
| Cumulative Free Cash Flow | $121.22B | $356.70B | $169.18B | $305.80B |
| Operating Cash Flow | $2.89B | $835.00M | $4.00B | $8.28B |
| Cash & Equivalents | $4.89B | $976.00M | $13.99B | $6.13B |